(S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid manufacturers
- CycLuc1
-
- $40.00
-
2026-07-15
- CAS:1247879-16-8
- Purity: 99.07%
- Supply Ability: 10g
|
| | (S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid Basic information |
| Product Name: | (S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid | | Synonyms: | Cyluc1 [(4S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydro-thiazole-4-carboxylic acid];CycLuc1(Luciferase substrate);Luciferase substrate;4-Thiazolecarboxylic acid, 2-(6,7-dihydro-5H-pyrrolo[3,2-f]benzothiazol-2-yl)-4,5-dihydro-, (4S)-;CycLuc1 (R)-2-(6,7-dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole- 4-carboxylic acid;CycLuc 1,inhibit,CycLuc1,Reactive Oxygen Species,Inhibitor,CycLuc-1;Luciferase Substrate, CycLuc1;CycLuc1, 10 mM in DMSO | | CAS: | 1247879-16-8 | | MF: | C13H11N3O2S2 | | MW: | 305.38 | | EINECS: | | | Product Categories: | | | Mol File: | 1247879-16-8.mol | ![(S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid Structure](CAS/20180601/GIF/1247879-16-8.gif) |
| | (S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid Chemical Properties |
| Boiling point | 606.8±65.0 °C(Predicted) | | density | 1.84±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 83.33 mg/mL (272.87 mM) | | pka | 3.54±0.20(Predicted) | | form | Solid | | color | Yellow to brown |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | (S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid Usage And Synthesis |
| Uses | Luciferase Substrate, CycLuc1 has been used for transfecting HEK293 cells to study the inhibition of intracellular luciferase crystallization by D-luciferin and its synthetic analogues. | | Biological Activity | Cell permeable: yes', 'Primary Target Luciferase | | in vivo | CycLuc1 (0.05-5 mM, intraperitoneally injected) can improve bioluminescence imaging (BLI) of the existing luciferase reporter protein in mice and achieve brain imaging that D-luciferin cannot achieve[2].
| Animal Model: | Mouse xenograft tumor models[2] | | Dosage: | 0.05, 0.5, 1, 5 mM, 100 μL | | Administration: | i.p. | | Result: | Yielded a >10-fold higher bioluminescent signal than could be obtained from D-luciferin injection at equivalent doses. |
| | storage | Store at -20°C |
| | (S)-2-(6,7-Dihydro-5H-thiazolo[4,5-f]indol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid Preparation Products And Raw materials |
|